ITK and B-cell chronic lymphocytic leukemia: Interestingly, ibrutinib has been found to boost T cell numbers and function in CLL, possibly through off-target effects on interleukin-2 inducible T cell kinase (ITK) or ZAP70, providing a rationale for concurrent treatment with CAR-T cells and ibrutinib (178).